SOLVO Biotechnológiai Zrt. – Trademark Portfolio
Entity Type: 99
SOLVO Biotechnológiai Zrt. holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 2 trademarks are registered and 3 are pending. Notable registered marks include SOLVO and TRANSELECT. The owner is based in Szeged.
Szeged H6726 , HU
Showing of trademarks Trademarks
Trademark Classifications
SOLVO Biotechnológiai Zrt.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does SOLVO Biotechnológiai Zrt. have?
SOLVO Biotechnológiai Zrt. has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 pending.
What trademark classes does SOLVO Biotechnológiai Zrt. file in?
SOLVO Biotechnológiai Zrt. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are SOLVO Biotechnológiai Zrt.'s most well-known trademarks?
SOLVO Biotechnológiai Zrt.'s registered trademark portfolio includes well-known marks such as SOLVO and TRANSELECT. These are among 2 currently registered trademarks in the portfolio.
What is SOLVO Biotechnológiai Zrt.'s trademark registration success rate?
SOLVO Biotechnológiai Zrt. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 3 applications are pending review.